Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03883919 · ClinicalTrials.gov registry record · Phase 1
Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy
A Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT03883919 is a Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 20 participants.
The verdict
NCT03883919, a Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
Given the efficacy of nanoliposomal irinotecan as a second-line regimen in pancreatic ductal adenocarcinoma (PDAC), together with the favorable toxicity profile of paricalcitol and its interplay with irinotecan metabolism, the investigators propose a second-line pilot study in advanced PDAC that will enroll patients who have progressed on a gemcitabine-based regimen.
Interventions
- DRUG Leucovorin
- DRUG 5-FU
- DRUG Paricalcitol
- DRUG Liposomal Irinotecan
- PROCEDURE Serum and plasma blood samples
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-07-11 |
| Est. Completion | 2022-07-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03883919
The ClinicalTrials.gov registry entry for NCT03883919 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Leucovorin is the first listed.
NCT03883919 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03883919 about?
NCT03883919 is a clinical study titled "Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy". Given the efficacy of nanoliposomal irinotecan as a second-line regimen in pancreatic ductal adenocarcinoma (PDAC), together with the favorable toxicity profile of paricalcitol and its interplay with irinotecan metabolism, the investigators propose a second-line pilot study in advanced PDAC that wil...
What is the current status of trial NCT03883919?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2019-07-11. Estimated completion is 2022-07-02.
What interventions are being tested in trial NCT03883919?
The interventions under investigation include: Leucovorin (DRUG), 5-FU (DRUG), Paricalcitol (DRUG), Liposomal Irinotecan (DRUG), Serum and plasma blood samples (PROCEDURE).
Who is sponsoring clinical trial NCT03883919?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.